We are live on
!
Find out more
BCM
Burrage Capital Management Portfolio holdings
AUM
$99.7M
1-Year Est. Return
66.05%
This Fund
S&P 500
This Quarter
Est. Return
+28.68%
1 Year Est. Return
+66.05%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$131M
AUM Growth
+$4.53M
(+3.6%)
Cap. Flow
-$13.5M
Cap. Flow
% of AUM
-10.25%
Top 10 Holdings %
Top 10 Hldgs %
64.4%
Holding
34
New
7
Increased
2
Reduced
15
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Protalix BioTherapeutics
PLX
|
+$8.85M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
+$5.7M |
| 3 |
INZY
Inozyme Pharma
INZY
|
+$4.07M |
| 4 |
Mirum Pharmaceuticals
MIRM
|
+$3.18M |
| 5 |
Intellia Therapeutics
NTLA
|
+$2.33M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AIMT
Aimmune Therapeutics
AIMT
|
+$11.5M |
| 2 |
OrthoPediatrics
KIDS
|
+$7.88M |
| 3 |
AnaptysBio
ANAB
|
+$4.88M |
| 4 |
Assembly Biosciences
ASMB
|
+$3.29M |
| 5 |
Regenxbio
RGNX
|
+$3.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
AnaptysBio
ANAB
$1.62B
| – | – |
-330,549
| Closed | -$4.88M |
|
|
27
Assembly Biosciences
ASMB
$524M
| – | – |
-16,667
| Closed | -$3.29M |
|
|
28
OrthoPediatrics
KIDS
$596M
| – | – |
-171,607
| Closed | -$7.88M |
|
|
29
Regenxbio
RGNX
$745M
| – | – |
-116,405
| Closed | -$3.2M |
|
|
CALT
30
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
| – | – |
-11,034
| Closed | -$265K |
|
|
KDNY
31
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| – | – |
-27,180
| Closed | -$330K |
|
|
TCDA
32
DELISTED
Tricida, Inc. Common Stock
TCDA
| – | – |
-188,182
| Closed | -$1.71M |
|
|
AIMT
33
DELISTED
Aimmune Therapeutics
AIMT
| – | – |
-332,546
| Closed | -$11.5M |
|
|
ZGNX
34
DELISTED
Zogenix, Inc.
ZGNX
| – | – |
-39,189
| Closed | -$703K |
|
Similar funds
WCM
CCM
RGM
TCM
RC
AC
QVT
WFWM
Burrage Capital Management's Q4 2020 Portfolio in Review
As of Q4 2020, Burrage Capital Management held 34 positions worth $131M, up 3.6% from $127M the previous quarter. Its ten largest holdings account for 64% of the portfolio.
Burrage Capital Management withdrew a net $13.5M in Q4 2020, closing 9 positions and reducing 15 holdings. Its most notable exit was Aimmune Therapeutics, an estimated $11.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 91% a quarter earlier.
Against the trend, Burrage Capital Management opened a new position in Protalix BioTherapeutics worth $8.97M.
- Burrage Capital Management's largest Q4 2020 buy was Protalix BioTherapeutics: 2,470,332 shares worth $8.97M.
- Burrage Capital Management added most to Lite Strategy Inc in Q4 2020, an estimated $481K increase.
- Burrage Capital Management's biggest Q4 2020 reduction was G1 Therapeutics, Inc. Common Stock, cutting an estimated $1.66M.
- Burrage Capital Management fully exited Aimmune Therapeutics in Q4 2020, selling an estimated $11.5M.
- Burrage Capital Management's ten largest holdings make up 64% of its $131M portfolio in Q4 2020.
- Burrage Capital Management opened 7 new positions and closed 9 in Q4 2020.
- Burrage Capital Management's portfolio value rose 3.6% quarter-over-quarter to $131M.
Based on Burrage Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.